MRK

Merck & Co. Inc. MRK logo

NYSE Healthcare

$119.94

+2.36 (+2.00%)

Updated: 3/31/2026, 4:00:01 PM

Open

$119.03

High

$121.25

Low

$117.73

Prev Close

$118.10

Volume

2.90M

Price History

Why Is MRK ▲ Up Today?

+2.00%

Full AI analysis generates after market close. Showing live price data.

Mar 31 ▲ +2.0% MRK Up Slightly Amidst Positive Sector Sentiment

Mar 30 ▼ -1.4% Merck (MRK) dips slightly amid sector gains, acquisition news

Mar 27 ▲ +0.6% Merck (MRK) Up Slightly Amidst Terns Acquisition News

Mar 26 ▼ -0.3% Merck (MRK) Dips Slightly Amid Terns Pharma Acquisition Uncertainty

Mar 25 ▲ +2.6% Merck (MRK) Climbs on Terns Pharma Acquisition

Mar 24 ▲ +0.6% MRK Up Slightly on Positive Sector Sentiment and New Collaboration

Mar 23 ▲ +1.3% MRK Up Slightly Amidst Mixed Sector Performance

Mar 20 — -0.0% MRK Dips Slightly Amidst Sector Weakness

Mar 19 ▼ -0.3% Merck (MRK) Down Slightly Amidst Mixed Sector Performance

Mar 18 ▼ -1.2% MRK Down Slightly Amidst Sector Weakness

Mar 17 ▲ +0.4% MRK up slightly despite sector downturn

Mar 16 ▼ -0.2% MRK Down Slightly Amid Mixed Sector Performance

Mar 13 — -0.1% MRK dips slightly despite positive sector news

Mar 12 ▼ -0.2% MRK Slight Dip Amidst Positive Analyst Outlook

Mar 11 ▼ -0.8% Merck (MRK) down slightly despite positive sector movement

Mar 10 ▼ -0.2% MRK Down Slightly Amidst Sector Weakness

Mar 9 ▲ +1.1% MRK Up Slightly Amid Positive Clinical Data and Analyst Optimism

Mar 6 ▼ -0.6% Merck (MRK) Down Slightly Amidst Sector Weakness and AI Collaboration News

Mar 5 ▼ -3.4% Merck (MRK) Drops Amidst Market Volatility and Sector Weakness

Mar 4 ▲ +0.4% MRK Up Slightly on AI Deal, Outperforming Sector

Mar 3 ▼ -1.8% MRK Down Slightly Amidst Sector Weakness

Mar 2 ▼ -2.2% Merck (MRK) Down Amidst Sector Weakness and Reorganization Concerns

Feb 27 ▲ +3.8% Merck (MRK) Climbs on Positive Data & Strategic AI Deal

Feb 26 ▼ -2.6% Merck (MRK) Drops Amid Profit Taking Despite Positive News

Feb 25 ▼ -1.4% Merck (MRK) dips slightly despite positive news, lagging sector

Feb 24 — +0.1% Merck (MRK) Gains Slightly Amidst Positive Data and Strategic Moves

Feb 23 ▲ +1.3% Merck (MRK) Rises on Strategic Reorganization and Clinical Advancements

Feb 20 ▲ +0.3% MRK Up Slightly Amid Positive Data and AI Deal

Feb 19 ▲ +0.6% Merck (MRK) Up Slightly Amidst Positive Data and AI Collaboration

Feb 18 ▲ +0.4% Merck (MRK) Up Slightly Despite Sector Weakness

Financial Highlights

Income Statement

Revenue

$64.23B

Gross Profit

$49.58B

77.2% margin

Operating Income

$21.82B

34.0% margin

Net Income

$19.04B

29.6% margin

EPS (Diluted)

$7.57

R&D Spend

$16.49B

Balance Sheet

Total Assets

$129.55B

Total Liabilities

$77.64B

Stockholders' Equity

$51.91B

Cash Flow

Operating Cash Flow

$17.07B

Investing Activities

-$3.98B

Net Cash Flow

$3.57B

Highly Regarded Analysis

Updated Apr 10, 2026 • Refreshes daily

Rating

Highly Regarded

Risk

Medium

Target

$127.59

Type

Standard

Executive Summary

Merck & Co., Inc. is a leading healthcare company with a strong presence in pharmaceuticals, vaccines, and animal health. The company faces the upcoming patent expiration of its key drug, Keytruda, in 2028, but is actively working to diversify its revenue streams through strategic acquisitions and pipeline development. Recent analyst ratings are positive, with a consensus of 'Moderate Buy'.

Bull Case

Merck's current stock price reflects a strong performance in the market and the company's recent quarterly earnings exceeded analysts' expectations, indicating robust financial health and operational efficiency. Analysts have upgraded their ratings for Merck, suggesting potential for appreciation. The company has a robust pipeline with over 80 Phase III trials.

Bear Case

Ongoing political scrutiny regarding drug pricing could impact long-term profitability. Insider selling activity may signal concerns about the company's future performance. The stock has a relatively high price-to-earnings ratio, which could indicate that it is overvalued compared to its earnings potential. Key franchises like Lenvima, Januvia, Lynparza and Gardasil also face loss of exclusivity.

Technical Outlook

The stock is currently trading above its 20-day, 50-day, and 200-day moving averages, indicating a bullish trend. The RSI is neutral, suggesting neither overbought nor oversold conditions.

Fundamental Health

Merck has a solid financial foundation with strong profitability and cash flow generation. The company's revenue grew by 5% compared to the same quarter last year. Merck's equity has increased by 14% YoY.

Key Catalysts

Positive clinical trial results
Strategic acquisitions
Successful pipeline development

Sources

tipranks.com trefis.com marketbeat.com fullratio.com seekingalpha.com finviz.com

This analysis was conducted by Highly Regarded's proprietary market analysis engine. It is not financial advice. Always do your own research and consult a financial advisor before making investment decisions.